premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

We reiterate KNSA as a TOP PICK following recently reported revenue growth of 165%, assisted by its drug success that reduces inflammation of the sac surrounding the heart.  It trades at 5x earnings and supports an 80% ROE.  We recommend trailing up the stop (from $15) to $16, looking to achieve $25 -- upside potential of 40%.  Yield 0%  

(Analysts’ price target is $25.40)
Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jun 29/23, Up 48.7%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with KNSA is progressing well.  To remain disciplined, we recommend trailing up the stop (from $13) to $15 at this time.  

Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

We reiterate this $1 billion marketcap pharmaceutical company as a TOP PICK.  Recently reported earnings beat expectations.  Analysts project annual revenue growth exceeding 25% for the next three years.  It trades under 3x book and supports a 70% ROE.  We recommend trailing up the stop-loss (from $10) to $13, looking to achieve $22 -- upside potential of 51%.  Yield 0%

(Analysts’ price target is $22.25)
Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Mar 16/23, Up 1.2%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with KNSA is progressing well.  To remain disciplined, we recommend trailing up the stop (from $9) to $10 at this time.  

Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O’Reilly

KNSA is a pharmaceuticals company that focuses on autoimmune and anti inflammatory diseases and cancers.  It is just now reaping the benefit of commercially released drug to help patients with inflammation of the sack around the heart.  It trades at only 5x earnings, has a ROE of 63% and is a low beta stock (acts more independently from the underlying equity market).  We recommend placing a stop-loss at $9, looking to achieve $22 — upside potential over 85%.  Yield 0%

(Analysts’ price target is $22.00)
Pharma & Healthcare
Showing 1 to 5 of 5 entries
  • «
  • 1
  • »

Kiniksa Pharmaceuticals(KNSA-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 2

Stockchase rating for Kiniksa Pharmaceuticals is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Kiniksa Pharmaceuticals(KNSA-Q) Frequently Asked Questions

What is Kiniksa Pharmaceuticals stock symbol?

Kiniksa Pharmaceuticals is a American stock, trading under the symbol KNSA-Q on the NASDAQ (KNSA). It is usually referred to as NASDAQ:KNSA or KNSA-Q

Is Kiniksa Pharmaceuticals a buy or a sell?

In the last year, 2 stock analysts published opinions about KNSA-Q. 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Kiniksa Pharmaceuticals.

Is Kiniksa Pharmaceuticals a good investment or a top pick?

Kiniksa Pharmaceuticals was recommended as a Top Pick by on . Read the latest stock experts ratings for Kiniksa Pharmaceuticals.

Why is Kiniksa Pharmaceuticals stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Kiniksa Pharmaceuticals worth watching?

2 stock analysts on Stockchase covered Kiniksa Pharmaceuticals In the last year. It is a trending stock that is worth watching.

What is Kiniksa Pharmaceuticals stock price?

On 2023-09-21, Kiniksa Pharmaceuticals (KNSA-Q) stock closed at a price of $17.14.